EdiGene (GuangZhou) Inc.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2018-03-05
- Employees
- -
- Market Cap
- -
- Website
- http://www.edigene.com
Clinical Trials
3
Active:1
Completed:0
Trial Phases
2 Phases
Phase 1:1
Not Applicable:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Not Applicable
2 (66.7%)Phase 1
1 (33.3%)A Study to Evaluate the Safety and Efficacy of ET-01 Transplantation in Subjects with Transfusion Dependent Β-Thalassaemia.
Not Applicable
Terminated
- Conditions
- Transfusion Dependent Beta-Thalassaemia
- Interventions
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- EdiGene (GuangZhou) Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT05752123
- Locations
- 🇨🇳
PLA 923 Hospital, Nanning, Guangxi, China
A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL)
Not Applicable
Active, not recruiting
- Conditions
- Relapsed or Refractory B-cell Malignancy(NHL/ALL)
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- EdiGene (GuangZhou) Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04933825
- Locations
- 🇨🇳
•The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
A Safety and Efficacy Study Evaluating ET-01 in Subjects with Transfusion Dependent Β-Thalassaemia
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- EdiGene (GuangZhou) Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT04925206
- Locations
- 🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, China
🇨🇳Shenzhen Children's Hospital, Shenzhen, Guangdong, China
News
No news found